A 44.1-month median progression-free survival in Grade 2 IDH-mutant glioma is not a number this disease has historically produced. For context, the original INDIGO readout at the 2023 data cut already turned heads; this extended analysis adds 21.3 months of unblinded follow-up and the PFS curve has not bent back down — it has stretched further, with the upper confidence interval still not estimable. That kind of durability in a low-grade glioma population that was, until recently, managed almost entirely by watchful waiting reframes what “early intervention” actually means for this histology.
The time-to-next-intervention data may be the most clinically consequential signal in the update. Only 23.8% of vorasidenib-treated patients had reached a next-intervention event by the January 2025 cutoff, and the median TTNI remains not estimable. That matters enormously for trial design downstream: if the standard-of-care arm in any future comparative study includes chemoradiotherapy, the bar for demonstrating additive benefit over vorasidenib alone rises steeply. The objective response rate of 20.8% — modest in absolute terms but improving with longer follow-up — also signals that IDH inhibition is producing genuine radiographic regression in a subset, not just disease stabilization. An additional 72.6% achieved stable disease, meaning total disease control sits above 93%.
The seizure data deserve separate attention. A 72% reduction in on-treatment seizure rate is not a secondary curiosity — it is a functional neurological outcome that directly affects employment, driving, and cognitive burden in a patient population with a median age at diagnosis often in the thirties or forties. The exploratory analysis stratifying by histology reveals a meaningful divergence: oligodendroglioma patients reached 6.9 seizures per person-year versus 17.5 for astrocytoma, with statistical significance only in the oligodendroglioma subgroup. That split will prompt questions about whether IDH1 versus IDH2 mutation status, or 1p/19q codeletion, is the operative biological variable driving differential seizure response — and it creates a real hypothesis worth testing prospectively.
The single marker to track from here is the astrocytoma subgroup’s seizure trajectory in any subsequent study. The oligodendroglioma signal is robust; the astrocytoma signal is not, and that gap, if it persists, will shape both label language and prescribing patterns for a drug that has otherwise built a clean long-term safety record with fewer than 5% of patients discontinuing due to adverse events.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
